Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The effects of pharmacist interventions on health outcomes in patients with advanced prostate cancer in Brazil

Full text
Author(s):
Patricia M Aguiar [1] ; Ana Luiza PM Mori [2] ; Maria GF de Lima [3] ; Magali SPN Rossi [4] ; Maria Aparecida Nicoletti [5] ; Karina OF Martins [6] ; Ana Lúcia M Lopes [7] ; Teresa Cristina M Coan [8] ; Oscar Eduardo H Fugita [9] ; Sílvia Storpirtis [10]
Total Authors: 10
Affiliation:
[1] University of São Paulo. School of Pharmaceutical Sciences - Brasil
[2] University of São Paulo. School of Pharmaceutical Sciences - Brasil
[3] University of São Paulo. School of Pharmaceutical Sciences - Brasil
[4] University of São Paulo. School of Pharmaceutical Sciences - Brasil
[5] University of São Paulo. School of Pharmaceutical Sciences - Brasil
[6] Secretariat of Health of the State of Sao Paulo - Brasil
[7] University of São Paulo. Teaching Hospital - Brasil
[8] University of São Paulo. Teaching Hospital - Brasil
[9] University of São Paulo. Teaching Hospital - Brasil
[10] University of São Paulo. School of Pharmaceutical Sciences - Brasil
Total Affiliations: 10
Document type: Journal article
Source: Brazilian Journal of Pharmaceutical Sciences; v. 58, 2022-04-22.
Abstract

Abstract This study examined the effects of pharmacist interventions for patients with advanced prostate cancer. A pre-post study was conducted between October 2014 and August 2017 in a community pharmacy in Brazil for outpatients with advanced prostate cancer, aged ≥ 18 years, using cyproterone acetate and/or goserelin. The patients had face-to-face meetings with a pharmacist who dispensed antiandrogenic drugs and performed interventions aimed at solving and/or preventing drug-therapy problems. Primary outcomes regarding prostate-specific antigen (PSA) and testosterone levels were compared at 0, 6, and 12 months, whereas secondary outcomes-medication adherence and quality of life-were compared at baseline and at the 12-month follow-up. Medication adherence was assessed using the Morisky-Green test, and quality of life was measured by the Medical Outcomes Study 36-item Short Form (SF-36) and the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The analysis included 20 patients; 311 drug-therapy problems were identified and most of them were related to adverse reactions (78.5%). The most common adverse reactions were reduced libido, erectile dysfunction, hyperglycemia, fatigue, and gynecomastia. Testosterone levels significantly decreased at 6 months, and PSA levels at 6 and 12 months. No significant changes in adherence were noted at the end of the study. A significant increase in the “pain” domain and an improvement trend in the “physical aspects” and “vitality” domains were observed based on the SF-36 instrument. The findings show that pharmacist interventions were able to improve PSA and testosterone levels, and some domains of quality of life of patients. (AU)

FAPESP's process: 12/51707-4 - Pharmacotherapeutic follow-up (pharmaceutical care) at the School Pharmacy of the University of São Paulo: phase IV clinical research, evaluation and proposal of the mechanisms for facing the judicialization process area in Brazil in partnership with São Paulo's Secretary of State of Health
Grantee:Silvia Storpirtis
Support Opportunities: Research Grants - Research in Public Policies for the National Health Care System (PP-SUS)